230 related articles for article (PubMed ID: 30591237)
1. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
Lee M; França UL; Graham RJ; McManus ML
Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
[No Abstract] [Full Text] [Related]
2. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
Pacione M; Siskind CE; Day JW; Tabor HK
J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M
Value Health Reg Issues; 2024 Jul; 42():100985. PubMed ID: 38669792
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
Aartsma-Rus A
Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
[No Abstract] [Full Text] [Related]
6. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
[TBL] [Abstract][Full Text] [Related]
7. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
[TBL] [Abstract][Full Text] [Related]
8. The End of the Beginning: The Journey to Molecular Therapies for Spinal Muscular Atrophy.
Pacak CA; Kang PB
Pediatr Neurol; 2020 Jan; 102():1-2. PubMed ID: 31481328
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
[TBL] [Abstract][Full Text] [Related]
10. Spinal muscular atrophy: A modifiable disease emerges.
Fitzgerald DA; Abel F; Jones KJ; Farrar MA
Paediatr Respir Rev; 2018 Sep; 28():1-2. PubMed ID: 30414816
[No Abstract] [Full Text] [Related]
11. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.
Darbà J; Marsà A
BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879
[TBL] [Abstract][Full Text] [Related]
12. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
14. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
Simoens S; Huys I
Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
[No Abstract] [Full Text] [Related]
15. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
Darbà J
Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing.
Friedmann T
Gene Ther; 2017 Sep; 24(9):503-505. PubMed ID: 28639617
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
19. New treatments for serious conditions: ethical implications.
King NMP; Bishop CE
Gene Ther; 2017 Sep; 24(9):534-538. PubMed ID: 28467402
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.
Richardson RC
JAMA Pediatr; 2018 Jul; 172(7):701. PubMed ID: 29801053
[No Abstract] [Full Text] [Related]
[Next] [New Search]
